A host of positive comments from a number of firms on the Street and an upgrade by Jefferies...

|By:, SA News Editor

A host of positive comments from a number of firms on the Street and an upgrade by Jefferies aren't enough for Onyx Pharmaceutical (ONXX -0.6%) to overcome a weak tape, poor phase III trial results on Tarceva and a Bernstein downgrade today. Despite the weak test results Jefferies still estimates a takeout valuation for Onyx at $122 per share, which is a 60% premium to its current $75.92 price.